LippmanSAWarnerMSamuelsSOliveDVercelliniPEskenaziB. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril. 2003;80(6):1488–1494.
2.
OnoMQiangWSernaVA. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012;7(5):e36935. doi:10.1371/journal.pone.0036935.
3.
WiseLAPalmerJRHarlowBL. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159(2):113–123.
4.
YangQMasADiamondMPAl-HendyA. The mechanism and function of epigenetics in uterine leiomyoma development. Reprod Sci. 2016;23(2):163–175.
5.
BarkerNMCarrinoDACaplanAI. Proteoglycans in leiomyoma and normal myometrium: abundance, steroid hormone control, and implications for pathophysiology. Reprod Sci. 2016;23(3):302–309.
6.
TsigkouAReisFMCiarmelaP. Expression levels of myostatin and matrix metalloproteinase 14 mRNAs in uterine leiomyoma are correlated with dysmenorrhea. Reprod Sci. 2015;22(12):1597–1602.
ZolfaghariNShahbaziSTorfehMKhorasaniMHashemiMMahdianR. Identification of differentially expressed K-Ras transcript variants in patients with leiomyoma. Reprod Sci. 2017;24(10):1438–1443.
9.
MaruoTOharaNYoshidaS. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system. Contraception. 2010;82(5):435–441.
